Spasov A A, Kucheriavenko A F, Salaznikova O A
Eksp Klin Farmakol. 2010 Aug;73(8):26-8.
The effects of hypoglycemic drugs (gliclazide, glibenclamide) and new sugar-lowering drug diabenol on the coagulation chain of hemostasis and fibrinolytic system of blood have been studied in intact rats and in rats with experimental diabetes mellitus. Experiments revealed the ability of drugs to reduce thromboelastogram indices, which is probably related to the ability of hypoglycemic drugs to inhibit the platelet aggregation and prevent the subsequent activation of the coagulation chain of hemostasis. All drugs improve the thrombogenic potential (by decreasing the platelet activation) and increase the activity of the fibrinolytic system of blood. The activity of diabenol and gliclazide i s more pronounced as compared to that of glibenclamide.
在健康大鼠和实验性糖尿病大鼠中，研究了降糖药物（格列齐特、格列本脲）和新型降糖药物二甲双胍对血液止血凝血链和纤维蛋白溶解系统的影响。实验表明，这些药物能够降低血栓弹力图指标，这可能与降糖药物抑制血小板聚集以及防止随后止血凝血链激活的能力有关。所有药物均改善了血栓形成潜能（通过降低血小板活性）并增强了血液纤维蛋白溶解系统的活性。与格列本脲相比，二甲双胍和格列齐特的活性更为显著。
